Koliko su učinkovite individualizirane doze hormona za žene koje pokušavaju zatrudnjeti in vitro oplodnjom (IVF)? Ključne poruke Nismo pronašli jasne dokaze koji bi poduprli ili odbacili upotrebu testova rezerve jajnika (engl. ovarian reserve tests, ORT) za odabir doze stimulacije, bilo za živo rođenje ili za sindrom hiperstimulacije jajnika (engl. ovarian hyperstimulation syndrome, OHSS). Buduća istraživanja mogla bi procijeniti učinak korištenja ORT-a za odabir doze stimulacije tijekom nekoliko pokušaja liječenja. Što je individualizirana stimulacija u IVF postupku? In vitro oplodnja (IVF)...

Je li terapija održavanja kronične limfocitne leukemije kod odraslih, nakon prethodno provedenog liječenja, bolje od promatranja tijeka bolesti bez intervencije ili placeba? Cilj Cochraneovog sustavnog pregleda Cilj ovog sustavnog pregleda bio je odrediti imaju li trenutno dostupni oblici terapije održavanja za kroničnu limfocitnu leukemiju kod odraslih osoba prihvatljiv omjer korisnih i štetnih učinaka nakon prethodno provedenog liječenja. Ključne poruke Ovim je pregledom utvrđeno da terapija održavanja nakon prethodnog liječenja kod odraslih s kroničnom limfocitnom leukemijom ima gotovo...

Title: Project Manager
Specifications: Permanent – Full Time
Salary: £42,000 per Annum
Location: UK/ London Remote Based Role
Directorate: CEOO
Closing date: 15 January, 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

To support the Evidence Production and Methods Department (EPM), Publishing and Technology department (P&T), Cochrane Library Product Manager and other Central Executive Teams (CET) in delivering on high priority projects: to project manage the highest priority EPM, P&T and other Cochrane projects where appropriate.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

• An opportunity to truly impact health globally.
• A flexible work environment.
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• Further information on the role and how to apply
• The deadline to receive your application is 15th January, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
• Read our Recruitment Privacy Statement

Wednesday, January 3, 2024 Category: Jobs

Cochrane warmly invites you to submit abstracts for oral presentations, posters, and workshops for the second Global Evidence Summit (GES) 2024. Hosted by global leaders in evidence synthesis and evidence-based practice, including Cochrane, JBI, Guidelines International Network (GIN), and The Campbell Collaboration, the summit is set to take place in the historical city of Prague, Czech Republic, from 10 to 13 September 2024, with satellite meetings on 9 September 2024.

This collaborative effort between esteemed organizations represents a unique opportunity for professionals across various sectors, such as health, education, social justice, the environment, and climate change, to engage in discussions about producing, summarizing, and disseminating evidence to inform policy and practice. Abstract and workshop submissions will be accepted until the extended deadline of  6 March 2024.

Dr. Karla Soares-Weiser, Vice Chair of the GES Scientific Committee and Cochrane Editor in Chief, extends an invitation to the Cochrane community, emphasizing the importance of their participation in this global event: 

As we open the doors for abstract submissions to the second Global Evidence Summit, I am thrilled to invite the Cochrane community to contribute to the exchange of ideas that will shape the future of evidence-based practice. This summit, uniting leading organizations in evidence synthesis, is a testament to our commitment to improving lives worldwide through the power of credible evidence. I encourage all Cochrane members and supporters to submit their abstracts for oral presentations, posters, or workshops, and join us in Prague for this exceptional opportunity to collaborate, learn, and drive positive change.

The themes for GES 2024 include:

• Sustainable development agenda
• The importance of research integrity making evidence accessible
• Power of synergy in evidence synthesis & synthesis products
• Evidence translation & implementation
• Advocating for greater evidence communication & use of evidence
• From global evidence to local impact
  
  
  
  

Catherine Spencer, Cochrane's CEO, emphasizing the significance of the GES in fostering synergies and knowledge sharing within the global evidence community:

Our recent Cochrane Colloquium in London was a testament to the vibrant spirit of the Cochrane community. In 2024, we are excited to co-host the second Global Evidence Summit alongside our esteemed partners. GES provides a crucial platform to address vital issues across sectors, while showcasing the incredible methods and work of Cochrane. I warmly invite all Cochrane members to participate actively and submit abstracts. Let's unite for #GES2024 and contribute to advancing evidence-based practice globally!

Abstracts and workshop submissions are open until 6 March 2024 with notifications of acceptances happening on 30 April 2024. 

• Oral and poster abstract details
• Workshop submission details
• Visit the GES Website

Thursday, February 29, 2024

Four global leaders in evidence synthesis and evidence-based practice, Cochrane, JBI, Guidelines International Network, and The Campbell Collaboration, invite you to join the eagerly anticipated 2nd Global Evidence Summit. These organizations are forgoing their annual conferences in 2024, and uniting once again to provide an event with a unique opportunity to exchange ideas about how best to produce, summarise and disseminate evidence to inform policy and practice, and use that evidence to improve people’s lives across the world. 

Hosted in the historical city of Prague, Czech Republic
at the stunning, modern O2 universum venue
on 10-13 September with satellite meetings on 9 September 2024

The summit will be multi-disciplinary and will bring together academics, researchers, and leaders across different sectors, including health, education, social justice, the environment, and climate change. Abstract and workshop submissions will open in early January. The themes for GES 2024 are:

• Sustainable development agenda 
• The importance of research integrity in making evidence accessible 
• Power of synergy in evidence synthesis & synthesis products 
• Evidence translation & implementation 
• Advocating for greater evidence communication & use of evidence 
• From global evidence to local impact

Catherine Spencer, Cochrane's CEO, extends a personal invitation to everyone in the Cochrane community: 

"It was wonderful to unite with the vibrant Cochrane community at our recent Cochrane Colloquium in London. In 2024, rather than hosting individual conferences, we take immense pride in co-hosting the 2nd Global Evidence Summit (GES) alongside some of our esteemed partners. This landmark event is scheduled to take place in Prague, Czech Republic, from 10 - 13 September with Satellite meetings on the 9 September.

We extend a warm and enthusiastic invitation to all our Cochrane members and supporters to mark these dates in their calendars and join us for what promises to be an extraordinary gathering of global minds. The GES serves as a pivotal platform for discussions spanning critical issues across various sectors, including health, education, social justice, the environment, and climate change.

Attending the GES will undoubtedly be of great benefit to our Cochrane community, fostering synergies and facilitating knowledge sharing within the global evidence community. I extend an invitation to explore the website, mark your calendars, and begin contemplating abstract submissions. Let's prepare to unite for #GES2024, actively shaping a future anchored in evidence-synthesis and collaborative efforts."

• Visit the newly launched GES website
• Subscribe to the GES 2024 newsletter

 

Thursday, December 21, 2023

Djeluju li intervencije za sprječavanje upotrebe elektroničkih cigareta kod djece i adolescenata? Ključne poruke Trenutno nema objavljenih randomiziranih kontroliranih ispitivanja koja procjenjuju učinak intervencija za prevenciju ili prestanak upotrebe e-cigareta među djecom i adolescentima. Međutim, pronašli smo 22 istraživanja te vrste koja su u tijeku i za koja se čini da ispunjavaju uvjete za buduća obnavljanja ovog sustavnog pregleda te mogu pružiti više odgovora. Cilj Cochraneovog sustavnog pregleda Željeli smo saznati koliko su intervencije bile učinkovite u prevenciji ili...

Još uvijek se čekaju dokazi o tome jesu li brusnice korisne za liječenje infekcija mokraćnog sustava Brusnice sadrže djelatnu tvar koja može spriječiti pričvršćivanje bakterija na stijenke mokraćnog mjehura. To može smanjiti infekcije mokraćnog mjehura i druge infekcije mokraćnog sustava (IMS). Brusnice (obično u obliku soka od brusnice) korištene su za pokušaj liječenja infekcija mokraćnog sustava, osobito kod visokorizičnih skupina poput starijih ljudi. Brusnice imaju malo nuspojava. Autori ovog pregleda nisu pronašli istraživanja u kojima su predstavljeni učinci soka od brusnice ili...

Specifications: Permanent – Full Time
Salary:  £60,000 per Annum  
Location: (Remote – Flexible) Ideally based in UK, Germany and Denmark. Candidates anywhere from the world will be considered; however, Cochrane’s Central Executive Team is only able to offer consultancy contracts outside these countries.
Closing date: 01 January 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into four directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

This role will lead the Membership, Learning & Support department in providing strategically-focussed services, providing intelligent pathways for people to get involved through membership, communicating and engaging with them in innovative ways to strengthen and develop their relationship with Cochrane, shaping and offering high quality learning experiences, and supporting people with their enquiries.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.  

You can expect: 

• An opportunity to truly impact health globally.  
• A flexible work environment  
• A comprehensive onboarding experiences.
• An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

• For further information on the role and how to apply
• The deadline to receive your application is 1st Jan, 2024.
• The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples. 
• Read our Recruitment Privacy Statement

Wednesday, December 13, 2023 Category: Jobs

Tuesday, December 12, 2023

Kakve učinke nadomjesna enzimska terapija ima na osobe s kasnijom pojavom Pompeove bolesti? Ključne poruke • Kasnija pojava Pompeove bolesti (engl. late-onset Pompe disease, LOPD) rijetko je stanje koje s vremenom uzrokuje pogoršanje stanja. Nadomjesna enzimska terapija (engl. enzyme replacement therapy, ERT) može usporiti napredak bolesti. • Alglukozidaza alfa (vrsta nadomjesne enzimske terapije) vjerojatno poboljšava neke aspekte napretka bolesti kod osoba s kasnijom pojavom Pompeove bolesti u usporedbi s placebom (neaktivnim ili 'lažnim' lijekom). • U budućim bi istraživanjima sudionike...

Koje su prednosti i moguće nuspojave korištenja diklofenaka u liječenju postoperativne boli kod djece? Ključne poruke • Zbog nedostatka čvrstih dokaza, prednosti i nuspojave korištenja diklofenaka u liječenju postoperativne boli kod djece nisu u potpunosti jasne. • Diklofenak vjerojatno smanjuje nuspojave mučnine i povraćanja, ali u usporedbi s drugim opioidima (poput morfija) može povećati rizik od krvarenja. • Potrebna su kvalitetno dizajnirana istraživanja i detaljna izvješća kako bi se utvrdile moguće prednosti i štetni učinci korištenja diklofenaka u usporedbi s opioidima ili drugim...

Wednesday, December 6, 2023

Operacija srca zbog zamjene aortnog zaliska kroz mali rez u odnosu na standardni puni rez na prednjem dijelu prsnog koša Ključne poruke - Nismo pronašli dovoljno dokaza visoke razine pouzdanosti kako bi odgovorili na pitanje o najboljem načinu zamjene aortnog zaliska, kroz standardni puni rez ili manji rez na prsnom košu. - Nijedan od bitnih problema koji se javljaju nakon operacije srca nije bio češći ni u jednoj skupini. Što je zamjena aortnog zaliska? Zamjena aortnog zaliska je rutinska operacija koja se izvodi radi zamjene jednog od srčanih zalistaka. Potreba za takvim zahvatom nastane...

Intervencije kojima se povećava i održava razina procijepljenosti u zemljama s niskim i srednjim dohotkom Koji je cilj ovog sustavnog pregleda? Cilj ovog Cochraneovog sustavnog pregleda bio je procijeniti učinak različitih strategija povećanja broja cijepljene djece u zemljama s niskim i srednjim dohotkom, kako bi se spriječile infekcije različitim bolestima. Cochraneovi istraživači su prikupili i analizirali sva povezana istraživanja kako bi odgovorili na ovo pitanje te su pronašli 41 relevantno istraživanje. Djeluju li strategije za poboljšavanje procijepljenosti djece? Milijuni djece u...

Liječenje akutne upale srednjeg uha (otitis media) antibioticima u djece Ključne poruke U zemljama s visokim dohotkom, većina djece s akutnom upalom srednjeg uha (engl. acute otitis media, AOM) spontano se oporavi bez komplikacija, a u usporedbi s placebom, antibiotici nemaju rani učinak na bol već samo blagi učinak na bol par dana kasnije. Sve dobrobiti antibiotika moraju se odvagnuti u odnosu na moguće štete: na svakih 14 djece liječene antibioticima jedno dijete doživjelo je nuspojave (poput povraćanja, proljeva ili osipa) koje se ne bi dogodile da im nisu dani antibiotici. U djece s...

Koji su učinci kortikosteroida za prevenciju postherpetične neuralgije? Ključne poruke • Ne zna se imaju li peroralni kortikosteroidi koji se daju tijekom akutne faze infekcije herpes zosterom ikakvog učinka na sprječavanje postherpetične neuralgije. • Peroralni ili intramuskularni kortikosteroidi mogu dovesti do male ili nikakve razlike u riziku od nuspojava kod osoba s akutnim herpes zosterom. Što je postherpetična neuralgija? Postherpetična neuralgija (PHN) je bolno stanje koje se može pojaviti nakon herpes zostera na području gdje je bio osip. Postherpetična neuralgija može perzistirati...

Usporedba dviju opcija liječenja bubrežnih kamenaca Što su bubrežni kamenci? Bubrežni kamenci su nakupine materijala koje sadrže kalcij, obično su tvrdi i mogu nastati u jednom ili oba bubrega. Bubrežni kamenci mogu nastati kada visoke razine određenih minerala tvore kristale u urinarnom traktu. Ovi kamenci mogu biti mali kao zrno pijeska ili veliki kao zrno graška. U rijetkim slučajevima mogu biti veliki poput loptica za golf. Mali bubrežni kamenci ne moraju uzrokovati simptome ili jaku bol. Veći kamenci mogu blokirati izlazak urina iz bubrega. Kako se liječe bubrežni kamenci? Ljudi s...

Infliksimab za liječenje aktivne Crohnove bolesti Ključne poruke – Infliksimab koji se koristi s purinskim analozima (azatioprin ili 6-merkaptopurin) vjerojatno je učinkovitiji od samih purinskih analoga za dovođenje Crohnove bolesti u remisiju. Također može biti bolji za ublažavanje simptoma. Ove dvije terapije mogu biti slične po pitanju sigurnosti. – Sami infliksimab može biti učinkovitiji od samih purinskih analoga za dovođenje Crohnove bolesti u remisiju i ublažavanje simptoma. Ove dvije terapije mogu biti slične po pitanju sigurnosti. – Infliksimab može biti jednako učinkovit poput...

Monday, December 4, 2023

Cochrane Crowd is a global community of volunteers who are helping to classify the research needed to support informed decision-making about health care. Cochrane Mexico recently hosted its third screening challenge that helped introduce students to randomized control trials and evidence assessment. This event not only fostered the value of evidence synthesis among students but also made a significant contribution to ongoing global research efforts. 


The job of the Cochrane Crowd community is to review descriptions of research studies to identify and classify randomized controlled trials (RCTs), a type of study that is considered the gold standard for clinical trials. Reports of RCTs are then fed into Cochrane’s Central Register of Controlled Trials, helping Cochrane authors and other systematic reviewers quickly find the evidence they need to determine whether a treatment works, or whether a diagnostic test is accurate.

Cochrane Mexico student event involved 31 universities  

The Cochrane Mexico Associated Centre at Sinaloa’s Pediatric Hospital,  the Autonomous University of Sinaloa, and the Mexican Association of Doctors in Training hosted their third Cochrane Crowd challenge. The first two challenges (held in 2018 and 2022) were limited to the Autonomous University of Sinaloa's students. This year, all Mexican medical schools were invited to participate and two students per university were selected.

59 students from 31 universities virtually participated, conducting 65,958 classifications in Cochrane Crowd in 24 hours. In total 3093 randomized clinical trials were identified. 59 medical students completed the 24 hours with more than 1000 classifications received Cochrane Memberships. First place was Pavel Martínez, from the Autonomous University of Chihuahua, who made 1104 classifications and had an accuracy of 97%.

Giordano Perez-Gaxiola, director of Cochrane Mexico and key challenge organizer, says: “Cochrane Crowd is a great introduction to systematic reviews and randomized control trials for students. Having students participate in a time-limited challenge is a fun way to engage students and was simple for us to set-up. The students exceeded all our expectations this year and we are so proud of them! Many of the students enjoyed it so much and could see results of their efforts for global health research that they are continuing to do screening on Cochrane Crowd!”

Anyone can join Cochrane Crowd and no previous experience is necessary

“Cochrane sends its thanks to all those involved in this citizen scientist challenge using Cochrane Crowd – what an amazing achievement in just 24 hours!” says Anna Noel-Storr, Cochrane’s Evidence Pipeline Lead. “We hope these students inspire everyone to give Cochrane Crowd a try. From medical students, to clinicians, to anyone with an interest in health research – being a part of Cochrane Crowd can help individuals develop skills in understanding health evidence while collectively contributing to global research efforts.” 

Has Cochrane Mexico inspired you to organise a Cochrane Crowd challenge at your workplace or university? If so, please get in contact and we will support you to get one up and running: crowd@cochrane.org

• Join Cochrane Crowd - everyone is welcome!
• If you teach evidence-based medicine, check out Cochrane Classmate, the platform we run challenges on.

Friday, December 1, 2023